Partnering and collaborating in the life science industry is essential for the development of innovative drug candidates. Since the beginning, ENYO Pharma has worked closely with several academic institutions, researchers, hospitals and private companies to build a strong portfolio in various therapeutic areas.
Indeed, ENYO Pharma has developed an innovative and disruptive drug discovery engine allowing to discover patentable molecules directed against new therapeutic intracellular targets.
Thus, ENYO Pharma is open to collaborate and partner to develop some of its molecules with different chemistry patterns coming from its unique approach. Please do not hesitate to contact us if you are interested.
Our current collaborations
In-Silico Scientific Solutions
ENYO Pharma works with In-Silico Scientific Solutions to analyse drug target interactions for the design of optimized molecules and for a deeper understanding of the compound impact on the target in multiple projects.
ENYO Pharma has signed a collaboration agreement with Novadiscovery, which consists in accelerating and de-risking the clinical development of EYP001, a bile acid receptor agonist (the farsenoid X nuclear receptor or FXR). (Learn more)
Our past collaborations
Charles River Laboratories International and ENYO Pharma have collaborated to identify the mode of action of ENYO Pharma’s lead preclinical chemical series, EYP002, using Charles River’s newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology. (Learn more)
ENYO Pharma SA
BIOSERRA 1 Bâtiment B
60 avenue Rockefeller
69008 LYON, FRANCE